# A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

> **NCT02038699** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Advanced Glioblastoma
- Advanced Colorectal Cancer
- Advanced Triple-negative Breast Cancer
- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** ONC201

## Key facts

- **NCT ID:** NCT02038699
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol not activated.
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038699, "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02038699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*